Ionis Pharmaceuticals Income Statement 2025-2011 | IONS

Brief overview of revenue and earnings at Ionis Pharmaceuticals

The comparison covers a five-year financial horizon. Revenue reported by Ionis Pharmaceuticals was 729 million dollars at the beginning of the period and 203 million dollars at the end. Across the full period, sales moved by −72.1%; the average annual rate was −22.5%. Sales followed a declining trajectory over the five years.

The gross result shifted from $717 million to $187 million, or −73.9%. Direct costs outpaced revenue, limiting the benefit of changes in sales. Comparing the endpoints gives gross margins of 98.4% and 92.2%. A lower margin indicates deterioration in the economics of the core business.

EBITDA was −159 million dollars at the beginning and −204 million dollars at the end of the period (−28.8%). Additional revenue translated efficiently into EBITDA. The EBITDA share of revenue changed from −21.8% to −100.6%. A lower EBITDA share weakens the quality of the result.

Comparing the endpoints shows a move from −$444 million to −$229 million. The negative result improved without reaching break-even.

Market value was 8.4 billion dollars at the start and 12.9 billion dollars at the end. Higher capitalization indicates improving investor confidence.

Summary assessment

The financial trajectory is weak and requires a cautious interpretation. The financial profile benefits from improving net profitability. The weaker side of the profile includes a softer top-line trend, a declining EBITDA margin and weaker gross profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.